Cite
HARVARD Citation
Krivorotko, P. et al. (n.d.). 319PA randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC). Annals of oncology. p. . [Online].